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 ABSTRACT  
Background and objectives: Treatment of spasticity poses a major challenge resulting 
from its complex clinical presentation and the variable efficacy and safety profiles of 
available drugs. We present a systematic review of the pharmacological treatment of 
spasticity in MS patients.  
Methods: Controlled trials and observational studies were identified using MEDLINE 
and Cochrane databases. Scientific evidence was evaluated according to pre-specified 
levels of certainty. Practical considerations are provided for the different interventions 
considered. 
Results: The evidence supports the use of baclofen, tizanidine and gabapentin as first 
line options for MS patients with spasticity. Diazepam or dantrolene could be 
considered if no clinical improvement is seen with the previous drugs. Nabiximols has a 
positive effect when used as add-on therapy in patients with suboptimal response or 
poor tolerance to first-line oral treatments. Despite methodological limitations in trials 
supporting their use, intrathecal baclofen and intrathecal phenol appear to show a 
positive effect in patients with severe spasticity and sub-optimal response to oral drugs. 
Local application of botulinum toxin or phenol injections can be beneficial in focal 
spasticity.  
Conclusions: The available studies on spasticity treatment offer some insight to guide 
clinical practice, but are of variable methodological quality. Large, well-designed trials 
with better assessment tools are needed to confirm the effectiveness of antispasticity 
agents and to inform the design of evidence-based treatment algorithms. 
BACKGROUND 
 
Spasticity results from damage to the upper motor neurons of the corticospinal tract 
with abnormal supraspinal driving of spinal reflexes, and affects around 34% of 
multiple sclerosis (MS) patients.1 It is characterized by increased muscle tone caused by 
hyperexcitability of the stretch reflex. It is often accompanied by weakness, pain and 
involuntary sudden movements (spasms) and, if severe, with contractures.2 Patients with 
spasticity may exhibit worsening of symptoms in the setting of underlying infection, 
such as urinary tract infections, or other noxious stimuli.3 
 
Different outcome measures are used to evaluate the degree of spasticity and its 
interference with function, including physician and patient-based scales.4 The most 
widely used is the (modified) Ashworth scale, which provides a semi-quantitative 
measure of the resistance to passive movement graded from 0 to 5, as perceived by the 
examiner. Other scales in use are the (modified) Tardieu scale 5; the Priebe and Penn 
scale6 and self-reported scales such as the Visual Analogue Scale, the Numeric Rating 
Scale or the Multiple Sclerosis Spasticity Scale (MSSS-88)7 which can address 
stiffness, clonus, spasms, pain and overall comfort. More complex techniques including 
the Wartenberg Pendulum tests, gait analysis or electromyography tend to be reserved 
for research purposes.8 
 
Optimum management of spasticity requires a multidisciplinary team (physiotherapist, 
nurse, neurologist, rehabilitation physician) and regular follow up.9 The goal of therapy 
is to increase functional capacity, facilitate rehabilitation, prevent contractures and 
relieve pain. The approach is usually multimodal, combining non-pharmacological and 
pharmacological interventions.10 An evaluation of the scientific evidence regarding 
physical therapy is beyond the scope of this review and detailed information can be 
found elsewhere.11  
 
We aimed to (i) review the current literature involving pharmacological treatment of 
spasticity, (ii) offer advice on best use of available agents based on the evidence and the 
consensus of the expert authors and (iii) identify methological limitations in the 
available evidence.  
METHODS (search strategy and consensus) 
 
Evidence was collected by searches for systematic reviews,  meta-analyses and original 
articles in MEDLINE and Cochrane databases before August 2013, using the search 
terms “multiple sclerosis”, “spasticity”, “spasm”, “muscular rigidity”, and their 
combinations, as well as abbreviations for the selected interventions (oral baclofen, 
tizanidine, dantrolene, benzodiazepines, gabapentin, cannabis-based drugs, botulinum 
toxin A, intrathecal baclofen and phenol injections). Additionally, the references of 
evaluated articles were screened for additional publications meeting the inclusion 
criteria.  
 
We included controlled trials and observational studies involving patients with MS and 
spasticity of any degree. Studies in non-English languages, using non-validated or not 
specified outcome measures were excluded, as well as those studies involving patients 
with spasticity not due to MS (unless MS patients were at least half of the sample).We 
extracted information regarding efficacy and side-effects for each of the selected 
interventions. 
 
Scientific evidence for antispasticity treatments was evaluated according to pre-
specified levels of certainty (class I, II, III, and IV).12 Due to the universal scope of this 
review, local issues such as costs and drug licensing were not taken into account when 
offering advice on use in clinical practice. Two independent investigators (SO and JS) 
evaluated the quality of evidence and wrote the initial draft that was evaluated by the 
chairman (XM) and circulated to the rest of the authors for further input, discussion and 
final agreement.  
  
RESULTS 
1. Centrally acting oral muscle relaxants 
Oral baclofen 
Oral baclofen is a structural analogue of gamma-aminobutyric acid (GABA) which 
crosses the blood-brain barrier and binds to pre- and postsynaptic GABA receptors, 
decreasing activity in motoneurons and interneurons. Control of symptoms is usually 
obtained with doses up to 60mg, with a maximum daily dose of 100mg.13 Twelve 
controlled trials were identified and, after exclusion of two studies (lack of outcome 
description14 and non-English language15), nine randomized16-24 and one non-
randomized25 controlled trials met the inclusion criteria. Of these, seven were placebo-
controlled trials16;18;20;21;23;24;25 and three were comparations with diazepam17;19;22. Six 
out of the 7 placebo-controlled studies16;18;20;23;24;25 showed a statistically significant 
improvement on spasticity when on baclofen compared with placebo, and one study, 
with a lower sample size, reported no differences21 (class II/III evidence).  Baclofen also 
improved the frequency of spasms and clonus18;23 (class III evidence).  
 
None of the three studies comparing baclofen and diazepam showed significant 
differences using the Ashworth or similar scales. 17;19;22 Similarly, there were no 
differences in the effect on the frequency of spasms between the two drugs19;22 (class III 
evidence). One of these trials compared high versus low doses of baclofen (30 or 60 mg) 
and diazepam (15 or 30 mg).17 While both doses showed a significant change in the 
Ashworth score before and after treatment, there was a marked improvement in those 
patients able to tolerate high doses (class III evidence).  
 In the majority of the analysed trials, baclofen showed an improvement in spasticity 
compared to placebo, with no differences compared to diazepam. However, the small 
size of the trials and the heterogeneity in the outcomes must be taken into account. Side 
effects, such as drowsiness, weakness, paresthesia, and dry mouth were common (10 to 
75%) and limited the maximum tolerated dose, but they were fewer and better tolerated 
than those caused by diazepam.26 
 
Tizanidine 
Tizanidine is a short-acting muscle relaxant which stimulates the central alpha2-
adrenergic receptors, leading to a reduced release of excitatory neurotransmitters at 
spinal and supraspinal levels. It is usually started at a dose of 2mg daily, increased up to 
a maximum dose of 36 mg daily with an average effective dose between 12mg and 
24mg.27   Thirteen trials met the inclusion criteria;  two evaluating tizanidine in single 
dose compared with placebo28;29 and 11 assessing the medium-term use of the drug (5–
15 weeks) compared with placebo 30-33, with diazepam 34 or with baclofen35-40.  
 
The two single dose studies28;29 showed significant dose-dependent improvement using 
the Pendulum test, but only the larger trial, involving 142 patients, showed an effect on 
the muscle tone (Class II evidence). The medium-term studies performed in the UK 
(187 patients) 33 and USA (220 patients) 31 evaluated treatment with tizanidine (titrated 
from 2 and 36 mg daily) compared to placebo over a 12 week period, using the 
Ashworth score. The UK study reported a significant reduction in muscle tone with 
tizanidine, while the USA study found no differences between groups. Both studies 
showed a greater, but nonsignificant, reduction in spasms and clonus in the treated 
group (class I evidence). It should be noted that the baseline muscle tone in the USA 
study was slightly higher in the placebo group and its decrease was greater than 
expected.  
 
In an additional placebo-controlled parallel trial (2-week washout period and a 3-week 
titration phase to a maximum dose of 32 mg per day) involving 66 MS patients, 
tizanidine showed a beneficial effect on spasticity without significant differences in the 
neurological status (Expanded Disability Status Scale –EDSS-)32 (class I evidence). In a 
further trial, testing sublingual and oral routes of administration, both had a positive 
effect compared to placebo in muscle tone, with no differences in walking speed (Timed 
25-Foot Walk test) or fatigue (Fatigue Severity scale score). Sublingual tizanidine 
showed a significant reduction in the next-day somnolence (modified Epworth 
sleepiness scale)30 (class II evidence). 
 
When compared with baclofen or diazepam, tizanidine showed a similar positive effect 
with no statistical difference between treatment groups. Several outcomes were 
considered, such as muscle tone, frequency of spasms and clonus, neurological 
disability, functional disability, physician’s assessment of clinical change and patient’s 
subjective perception (class II evidence)34-40.  
 
In summary, tizanidine was superior in the short and medium term compared to placebo 
and equally effective compared to diazepam or baclofen. Side effects (mainly related to 
its alpha2-adrenergic activity including drowsiness and dry mouth) were dose-related. 
Decreases in blood pressure and heart rate were also reported, as well as transient 
increases in hepatic transaminase levels, with normalization following discontinuation 
of treatment.41 
 Benzodiazepines 
Diazepam enhances the effect of the neurotransmitter GABA and suppresses neuronal 
activity in the reticular formation, contributing to muscle relaxation. The maximum 
recommended dose is 30 mg per day, with an average dose of 15 mg.10 In the initial 
search, eight trials were identified and the only placebo-controlled trial42 was excluded 
(only 4 out of 21 patients had MS).  The remaining studies used baclofen17;19;22, 
tizanidine34, dantrolene43 and ketazolam.44;45 as active comparators. 
 
As described previously, both diazepam and baclofen showed a positive effect on 
spasticity with a similar safety profile, despite more sedation observed with diazepam 
(class III evidence)17;19;22. When compared with dantrolene, tizanidine or ketazolam, 
diazepam also produced a similar reduction in spasticity (class II/III evidence)34;43;44;45.  
 
Gabapentin 
Gabapentin is structurally similar to GABA, exerting GABAergic activity by binding 
receptors in the neocortex and hippocampus. The normal starting dose is 300 mg per 
day escalated up to a maximum daily dose of 3600 mg.46 Five studies were identified 
and three were excluded for methodological reasons (open-label trials47;48 and case 
report49). The analysed studies were randomized, placebo-controlled short-duration 
crossover trials.50;51 The higher dose study50 (up to 900 mg gabapentin orally three times 
daily over a 6-day period) reported a significant effect in all physician-assessed 
measures and subject-reported outcomes. The lower dose study51 (400 mg gabapentin 
orally three times daily for 48 hours) also reported a decrease in the modified Ashworth 
score, but no effect on clonus, reflexes or response to noxious stimuli (Class II 
evidence). The main adverse effects were drowsiness, somnolence and dizziness but it 
was generally well tolerated, with no serious side effects reported.50;51 
 
Considering this evidence regarding centrally acting oral muscle relaxants, several 
practical recommendations can be made. In patients who experience spasticity, baclofen 
could be considered as one of the first treatment options. Due to the potential risk of 
dose related side effects, treatment should be initiated at low dose (5-10 mg daily) and 
gradually titrated upwards to a maximum of 100 mg per day.13 Tizanidine may also be 
used as an alternative to baclofen, given the similarities in efficacy and global 
tolerability between both drugs. Dose related side effects and individual variation in the 
tolerated dose prove the need to start tizanidine at 2mg daily and slowly increase to a 
maximum of 36 mg. Given the risk of hepatic dysfunction, present recommendations 
include monitoring of liver function monthly for the first six months of treatment and 
periodically thereafter.52 Gabapentin can be an alternative to baclofen and tizanidine, 
based on its clinical effect and safety profile, but no head to head comparations between 
gabapentine and other drugs are available. In light of the higher risk of side effects, 
diazepam could be considered in patients where no clinical improvement is seen with 
oral baclofen, tizanidine or gabapentin. The authors of this document agree that a step-
wise approach to therapy favouring monotherapy is preferred to a combination of drugs. 
As inclusion criteria are not homogeneous in the available studies, the general 
indication would be to start treatment if there is interference with activities of daily 
living (basic and/or instrumental) or if the patient suffers from significant pain. See 
figure 1 for spasticity treatment algorithm. 
 
 
2. Peripherally acting oral muscle relaxants 
Dantrolene 
Dantrolene acts on the contractile mechanism of skeletal muscle, decreasing the release 
of calcium. Treatment regimes are usually started at 25 mg once daily and increased 
gradually to a maximum of 400 mg divided into four doses.53 Six studies were identified 
and three were excluded (open trial design54 or MS patients representing less than half 
of the study sample55;56). 
 
Two small studies, a crossover (20 patients)57 and a parallel-group trial (23 patients)58, 
compared dantrolene with placebo, starting at 50 mg or 25 mg four times a day, 
respectively, and titrated to a maximum of 100 mg. The crossover trial only provided 
patients’ preferences (35% chose dantrolene over placebo, 20% preferred placebo and 
45% had no preference)57 (class III evidence). In the parallel-group study, a reduction in 
a spasticity semi-quantitative scale was observed in 42% of patients on dantrolene, and 
27% on placebo58 (class III evidence).  
 
A later trial compared dantrolene versus diazepam using a fixed increasing dosage 
schedule over a two-week period, followed by another 2 weeks of maximum dose43.  
Both dantrolene and diazepam reduced spasticity and reflexes at low and high doses, 
but this reduction was significantly greater with dantrolene at higher doses.  Subjective 
improvement was reported for two categories (muscle spasms or cramps and stiffness) 
with no statistical difference between drugs (Class II evidence).  
 
Dantrolene proved superior to placebo using objective and subjective measures, based 
on low quality evidence. The usage of dantrolene is restricted due to the frequency of 
side effects, such as gastrointestinal symptoms, weakness, fatigue, sedation and 
dizziness. The risk of hepatotoxicity is the major limitating factor and requires 
monitoring of liver function prior and during therapy.53,59 As a consequence, the 
evidence would support the use of dantrolene only in patients where no clinical 
improvement is seen with oral baclofen, tizanidine or gabapentin (see figure 1 for 
spasticity treatment algorithm). Given that weakness is a frequent side effect, dantrolene 
may be reserved for non-ambulatory patients.  
 
 
3. Cannabis-based drugs 
Several pharmacological products with cannabinoid-receptor mediated effects 
containing D9-THC and cannabidiol (CBD) or synthetic D9-THC (dronabinol) are now 
available.60 We identified 13 studies involving cannabis-based drugs for the treatment 
of spasticity in MS. Four were excluded ( observational studies61;62 a preliminary trial,63 
or MS patients representing less than half of the sample64) A total of 8 randomized 
placebo-controlled studies65-72 and one metaanalysis73 were considered. 
  
The first available studies were a crossover trial using low doses of dronabinol 
(Marinol®) or a C sativa plant extract66; a large multicenter placebo-controlled trial 
(CAMS study, UK) using oral cannabis extract, delta9-tetrahydrocannabinol or placebo 
over 15 weeks71 (and its subsequent follow-up study during 12 months72); and a single-
centre placebo-controlled crossover study of cannabis-extract capsules containing 
tetrahydrocannabinol (THC) and cannabidiol (CBD).69 They all used the mean change 
in the Ashworth score, showing no significant change at the end of the treatment period 
(class II evidence). However, they showed a significant improvement in spasticity, pain, 
sleep disruption or spasms using self-completion questionnaires66;69;71 (class II 
evidence). A significant treatment effect in the timed 10-meter Walk Test at 15 weeks 
(available for 278 out of the 630 patients) was seen in the CAMS study, but was no 
longer significant in the 12 month follow-up72 (class II evidence).  
 
Nabiximols (Sativex®) is an oromucosal spray of cannabis extract containing THC and 
cannabidiol. Therapy usually starts with a 2-week dose titration phase up to a maximum 
daily dose of 12 sprays.74 Nabiximols was initially tested against placebo in MS patients 
with a variety of symtoms (spasticity, spasms, bladder problems, tremor or pain) 
evaluating the change in the Visual Analogue Score of their most troublesome 
symptom.70 Patients on active treatment and spasticity showed a significant reduction in 
their Visual Analogue Score that could not be confirmed with the Ashworth scale (class 
I evidence). The Numeric Rating Scale was used as primary outcome in two further 
trials showing a significant improvement and highlighting the difference in the 
proportion of responders (defined as ≥ 30% reduction on the Numeric Rating spasticity 
score) between the nabiximols and placebo groups75;76(class I evidence).  These three 
trials were combined in a meta-analysis, including 666 patients, that confirmed the 
overall eficacy of nabiximols.73 
 
To overcome the possible underestimation of drug efficacy in previous studies, a recent 
trial used an enriched study design, selecting responders (at least 20% reduction in 
mean Numeric Rating score) in a single-blind study phase.68 These patients were 
subsequently randomized in a double blinded phase to nabiximols or placebo over a 12 
week period with a resulting significant superiority of nabiximols over placebo 
according to the Numeric Rating Spasticity Scale. Nabiximols also had a better impact 
on spasm frequency, sleep disruption and the Barthel Scale68 (class I evidence). 
 
Finally, in a 5-week withdrawal study, patients on long-term treatment with nabiximols 
were blindly randomized to nabiximols or placebo.67  Treatment failure (defined as 
either cessation of treatment, 20% increase in spasticity, or taking additional 
medication) was present in 94% subjects from the placebo group compared to 44% in 
the nabiximols group. The time to treatment failure significantly favoured nabiximols 
(class I evidence). 
 
In summary, nabiximols showed a positive effect without serious adverse events in 
recent high class trials with an enriched study design, where it was used as an add-on 
therapy. However, there was an increased incidence of non-serious adverse events, with 
dizziness the most frequently reported.77 This evidence would support its use in MS 
patients with spasticity and a suboptimal therapeutic response or poor tolerance to oral 
drugs (baclofen, tizanidine and gabapentin) (See figure 1 for spasticity treatment 
algorithm). The therapeutic response must be evaluated after 4 weeks, as only less than 
50% of patients are responders, and discontinuation should be considered if no 
significant symptom improvement is seen. It is noteworthy that an influential review by 
NICE in the UK78 accepted the data on nabiximols in terms of efficacy and safety. Their 
final recommendation that the drug not be used was made solely on grounds of its not 
meeting cost-efficacy requirements. We are aware that access to, and reimbursement of 
this drug, varies among healthcare systems more than others reviewed. 
 
 
4. Peripherally acting injected muscle relaxants 
Botulinum toxin  
Botulinum toxin type A blocks release of acetylcholine at neuromuscular junctions 
inhibiting muscle contraction. Local injection of botulinum toxin A in isolated muscles 
has a lasting effect over several weeks with complete reversibility.79 Five studies were 
identified in the initial search and three were excluded (case-series design,80 MS 
patients representeing less than half of the sample81 and open-label uncontrolled 
design82) . 
 
Two placebo-controlled randomized trials were available.83;84 Botulinum toxin (400 
MU)  tested in 10 chair-bound or bed-bound patients decreased the spasticity score and 
eased patient care83 (class III evidence). The other trial evaluated three treatment arms 
(500, 1000 and 1500 MU) versus placebo on hip adductor spasticity.The modified 
Ashworth scale and spasm frequency improved to a similar extent in all four groups, but 
significant changes were only observed in muscle tone for the botulinum toxin groups. 
Time to re-treatment was significantly longer for all treatment doses compared with 
placebo (class I evidence).84  
 
Only two trials evaluated Botulinum toxin in MS, involving a small number of patients 
over a short period of time. Nevertheless, the observed effects and the safety profile 
(similar to placebo with the exception of muscle weakness84), would support the use of 
local application of botulinum toxin A in patients with MS and focal spasticity of the 
lower limbs (see figure 1 for spasticity treatment algorithm). Botulinum toxin injection 
demands excellent knowledge of anatomy and function and physicians offering the 
treatment should be trained in its use. 79 
 Local phenol injections 
Phenol injected in motor points of selected muscles leads to axonal damage. Solutions 
between 5-8% phenol produce a selective effect, that can be maximized by combining 
phenol with glycerin which limits its spread.85 No randomized controlled trials were 
identified evaluating the effect of phenol injections on spasticity due to MS or other 
causes.  Given the lack of higher grade evidence, case series and observational studies 
were considered. Four studies were identified and two were excluded (lack of adequate 
description of the study population86 and not adressing the topic of interest87). The 
remaining two studies were a case series88 and a prospective study.89 
 
The case series included 69 patients reporting a general relief of spasticity lasting from 
3 to 14 months in the majority of patients (class IV evidence).88 The prospective study 
included 62 patients followed over three months after phenol injection showing a 
significant reduction in the spasticity of hip adductors after the first week, with a 
maximum improvement after the first month. An important increase in the range of 
motion values for hip abduction was observed (class IV evidence).89  
 
The evidence supporting the use of phenol injections for the treatment of spasticity is 
limited and of very low quality. Nevertheless, these studies showed a positive effect in 
reducing spasticity, spasms and pain in a high proportion of patients. Adverse effects 
were uncommon and temporary, with dysesthesia the most frequently reported.  
Therefore, phenol injections could be considered as an alternative to botulinum toxin in 
the management of focal spasticity, but higher quality evidence is needed to fully 
support its use. 
 5. Intrathecal therapies 
Intrathecal baclofen 
Since baclofen does not cross the blood-brain barrier effectively, intrathecal 
administration achieves much higher concentrations in the cerebrospinal fluid. A 
surgically implanted pump with reservoir allows four times the concentration of drug at 
1% of the oral dosage. Pump implantation is considered only after testing 
responsiveness and optimal individual doses. Treatment is started at a dose of 25 µg per 
day, increasing over the first 6 months up to an average of 400 to 500 µg daily.46  
 
Three randomized-controlled trials met the inclusion criteria90-92 and all examined the 
effect of baclofen administered intrathecally by a programmable infusion pump after an 
initial screening stage to test responsiveness. In a long-term multicentre placebo-
controlled trial including 22 patients, the active treatment group showed a significant 
improvement in the Ashworth score, the spasms score and the self-reported pain score 
(class I evidence) 91. These results were confirmed in a larger multicentre trial90 (class 
III evidence) and in a short-term placebo-controlled crossover trial92 (class II evidence).  
 
Intrathecal baclofen appears to show a beneficial clinical effect in patients with severe 
spasticity, accepting some limitations in the analysed studies including a failure to 
justify the sample sizes and a lack of published direct head-to-head comparisons. Side 
effects caused by the drug itself are uncommon, being drowsiness, dizziness, blurred 
vision and slurred speech the most frequently reported. Technical complications include 
those related to the surgical procedure, dysfunction of the pump and catheter-related 
issues.90;93 The implantation of an intrathecal baclofen pump to relieve lower limb 
spasticity could be considered if suboptimal response to oral drugs is observed. Prior to 
implantation, its efficacy must be evaluated by way of an intrathecal baclofen test and, 
in patients with walking ability this test must be performed using an external pump 
which allows the functional performance of the patient to be evaluated 94. The authors 
of this document agree that a careful selection of patients based on the identification of 
realistic and mutually agreed treatment goals is recommended. 
 
Intrathecal phenol 
No randomized controlled trials evaluating the effect of intrathecal phenol on spasticity 
due to MS or other causes were identified and four observational studies were 
reviewed.95-98 Two case series reported descriptive results in terms of general relief of 
spasticity (class IV evidence).95;96  A cross-sectional observational study compared an 
initial phenol injection (initial group) versus subsequent injections (serial group) in five 
muscle groups, in both targeted and non-targeted sides, showing a significant reduction 
in the Ashworth score in both groups.97 (class IV evidence). Finally, in a retrospective 
study, 40 patients treated with intrathecal phenol showed improvement using a simple 
rating scale and by attainment of rehabilitation goals (class IV evidence).98  
 
Evidence supporting the use of phenol intrathecal injections is limited and of very low 
quality. This drug should be reserved for MS with severe spasticity and suboptimal 
response to oral drugs who do not show benefit after an intrathecal baclofen test, for 







Spasticity is a complex phenomenon resulting in a large inter- and intra-individual 
variability in the responses to therapeutic interventions. Overall, the methodological 
quality of the studies described was poor, with small sample sizes and short duration, 
which limits inference of long-term efficacy. There was also marked heterogeneity in 
patients’ characteristics and treatment regimens. The difficulty in the quantification of 
spasticity is reflected in the wide variety of approaches taken to assess this symptom 
and in the global discrepancy between relief of spasticity and improvement of the 
neurological status. Furthermore, a discrepancy between published evidence and the 
daily experience of those who manage spasticity was also evident. There is a need for 
large, well-designed trials with better assessment tools that incorporate functional 
ability and patient’s quality of life, to confirm the effectiveness of the widely used 
antispasticity agents.  
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1. Using validated scoring systems to determine the level of spasticity and evaluation of its impact on 
functioning. It is important to evaluate the beneficial and/or harmful effects of spasticity from a functional 
perspective as it is not always a disabling symptom/sign. In some cases, spasticity may have beneficial 
effects and improve the performance status of the patient.  
2. Specific treatment of the aggravating factor (ie. antibiotics for urinary infection). 
 
Adapted from: Clinical practice guideline on the management of people with Multiple Sclerosis99 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
